This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Chiesi Group, Kindeva Drug Delivery, and H&T Presspart (a division of the Heitkamp & Thumann Group) are partnering on the installation of a production line for dose counter (DC) and dose indicator (DI) devices. Combining the specific expertise of each partner, H&T Presspart will manufacture Kindeva Drug Delivery’s dose counters under license for Chiesi Group for its pressurized metered-dose inhaler (pMDI) portfolio.
H&T Presspart will expand the cleanroom facilities at its Marsberg, Germany, site to support the dose counter production. As part of this strategic partnership, Chiesi Group will use dose counters in their innovative carbon minimal pMDI portfolio, which uses a low Global Warming Potential (GWP) propellant to minimize the climate impact of the inhalers, while maintaining all the therapeutic options that patients suffering from respiratory diseases need.
The partnership is a continuation of an agreement signed in 2014 between Kindeva Drug Delivery and H&T Presspart to accelerate the growth of Kindeva Drug Delivery’s dose counter technology, which enhances patient safety by providing real-time information on the remaining doses in inhalers, preventing unexpected shortages.
“Kindeva is pleased to extend this strategic partnership as it solidifies our core objective of improving the lives of patients around the world,” says David Stevens, global chief commercial officer of Kindeva Drug Delivery. “Kindeva embraces the responsibility it has in ensuring that patients who depend upon our device technology are reliably supplied, and we believe that this innovative supply chain collaboration further underscores this commitment.”
“Chiesi, with its patient-centric approach, is dedicated to delivering therapeutic solutions that enhance patients’ health and quality of life,” adds Roberto Della Valle, head of global direct procurement of Chiesi Group. “Collaborating with Kindeva and H&T Presspart exemplifies this commitment, and we are thrilled to take this step forward. By providing an inhaler that reassures patients about the remaining dose count, we aim to enhance their safety and confidence.”
Christian Kraetzig, president of H&T Presspart, comments, “With our expertise in device industrialization and manufacturing, this agreement marks another step in our journey to becoming a leading development and contract manufacturing partner in drug delivery devices.”
